FIELD: biotechnology.
SUBSTANCE: anticancer fusion protein and a pharmaceutical composition comprising it are disclosed. Anticancer fusion protein contains a first monomer comprising a variant of IL-12, and a second monomer comprising an antigen-binding site which specifically binds to FAP. Also disclosed are polynucleotides coding the fused protein, vectors and transformed cells for producing the fused protein.
EFFECT: fused protein according to the invention has high anticancer activity and can be used for anticancer therapy.
28 cl, 34 dwg, 12 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR RELIEVING OR TREATING PAIN | 2017 |
|
RU2725830C1 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| VARIANT OF ALDOLASE AROG AND METHOD OF PRODUCING BRANCHED-CHAIN AMINO ACID USING SAME | 2021 |
|
RU2826456C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| NEW O-SUCCINYL HOMOSERINE TRANSFERASE VARIANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID VARIANT | 2018 |
|
RU2747493C1 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| NEW O-SUCCINYL HOMOSERINE TRANSFERASE MUTANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID MUTANT | 2018 |
|
RU2747494C1 |
